Facilitating Innovative Nuclear Diagnostics Act of 2021

United States117th CongressHR-4479House of Representatives
Updated: Jul 19, 2021

Summary

Facilitating Innovative Nuclear Diagnostics Act of 2021 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2022 and as adjusted based on a specified fee schedule factor in each year thereafter.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

Latest companion bill action

S-2609: Facilitating Innovative Nuclear Diagnostics Act of 2021

Introduced in Senate

  1. Introduced in House

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

  4. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.